文献速递产科母胎医学

通过产前基于单核苷酸多态性的游离DNA筛查识别全基因组父源单亲二体

Whole-genome paternal uniparental disomy identified through prenatal single-nucleotide polymorphism-based cell-free DNA screening.
PubMed 文献 · Ultrasound Obstet Gynecol · 2025-11-26

本研究回顾性分析了单一商业实验室2014年6月至2023年11月间所有报告为双胎或三倍体且疑似全基因组父源单亲二体(GW-UPDpat)的cfDNA筛查结果,共89例,经SNP图重新解读排除12例三倍体后剩余77例,其中24例有随访信息,21例(87.5%)超声和/或病理发现与完全性葡萄胎合并共存胎儿(CHMCF)一致。结论认为基于SNP的cfDNA筛查有助于识别CHMCF并区分CHMCF与三倍体,但这些初步观察无法评估该检测的敏感性或阳性预测值。

要点

  • 基于SNP的cfDNA筛查可提示GW-UPDpat,有助于识别CHMCF并与三倍体鉴别。
  • 77例中24例有随访,21例(87.5%)超声和/或病理与CHMCF一致。
  • 胎儿cfDNA分数常很低(28例≤2%),葡萄胎cfDNA分数范围为10-58%。

核心结论

  • 基于SNP的cfDNA筛查有助于识别CHMCF并区分CHMCF与三倍体。
  • 对于CHMCF,早期发现对于评估不良结局和妊娠滋养细胞肿瘤风险很重要。
  • 部分检测阳性病例可能包括未被识别的PMD或嵌合/奇美拉GW-UPDpat综合征。
  • 这些初步观察无法评估该检测的敏感性或阳性预测值。

研究设计与样本

  • 回顾性研究,纳入单一商业实验室2014年6月至2023年11月间所有报告为双胎或三倍体且疑似GW-UPDpat的cfDNA筛查结果。
  • 共审查5,699,009例检测,其中89例报告为双胎或三倍体且疑似GW-UPDpat。
  • 经SNP图回顾性重新解读排除12例三倍体(额外一套父源染色体),剩余77例。
  • 77例中24例有随访妊娠信息。

主要发现

  • 24例有随访信息者中,21例(87.5%)超声和/或病理发现与CHMCF一致。
  • 胎儿cfDNA分数常很低,28例≤2%。
  • 葡萄胎cfDNA分数范围为10-58%。
  • 胎儿性别为男性35例、女性40例、不确定2例。
  • 所有77例均显示等二体,无一例显示杂二体区域的明确证据。

局限性

  • 这些初步观察无法评估该检测的敏感性或阳性预测值。
  • 部分检测阳性病例可能包括未被识别的PMD或嵌合/奇美拉GW-UPDpat综合征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Prenatal single-nucleotide polymorphism (SNP)-based cell-free DNA (cfDNA) screening can identify genome-wide paternal uniparental disomy (GW-UPDpat), including cases with complete hydatidiform mole with a coexisting fetus (CHMCF), those with placental mesenchymal dysplasia (PMD) and those with a mosaic/chimeric GW-UPDpat syndrome. Our objective was to review laboratory data and pregnancy outcome for SNP-based cfDNA screening tests with results compatible with GW-UPDpat and a normal cell line. METHODS: This was a retrospective study of all cfDNA screening results from a single commercial laboratory between June 2014 and November 2023 that were reported as twins or triploidy, with apparent GW-UPDpat. Two-dimensional representations of the relative ratios of SNP alleles (SNP plots) were used to identify and quantify the proportion of cfDNA from the mole ('molar fraction') and that from the coexisting non-molar pregnancy ('fetal fraction'). Test referral and follow-up information, including ultrasound findings, laboratory testing and pregnancy outcome, were reviewed. RESULTS: Of 5 699 009 tests reviewed, 89 were reported as twins or triploidy, with apparent GW-UPDpat. Retrospective review of SNP plots excluded 12 cases that were reinterpreted as triploidy with an extra set of paternal chromosomes. Of the remaining 77 cases, 24 had follow-up pregnancy information available, and of these, 21 (87.5%) had ultrasound and/or pathology findings that were consistent with CHMCF. The fetal cfDNA fraction was often very low (≤ 2% in 28 cases). The molar cfDNA fraction was in the range of 10-58%. Fetal sex was male in 35 cases, female in 40 cases and uncertain in two cases. No case showed clear evidence of a Y-chromosome in the GW-UPDpat line. All 77 cases had isodisomy; none showed clear evidence of regions of heterodisomy. CONCLUSIONS: SNP-based cfDNA screening can help to identify CHMCF and distinguish between CHMCF and triploidy. For CHMCF, early detection is important for evaluating the risk of adverse outcome and gestational trophoblastic neoplasia. Some of our test-positive cases could have included unrecognized PMD or mosaic/chimeric GW-UPDpat syndrome. These preliminary observations do not allow assessment of the sensitivity or positive predictive value of this test. © 2025 Natera, Inc. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Benn P, Hashimoto K, Souter V, et al. Whole-genome paternal uniparental disomy identified through prenatal single-nucleotide polymorphism-based cell-free DNA screening. Ultrasound Obstet Gynecol. 2025. PMID: 41299888. doi:10.1002/uog.70144

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。